S 2032
116th Congress
Senate
Crime and Law Enforcement
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health personnel
Health programs administration and funding
Licensing and registrations
Medical research
Public-private cooperation
Research administration and funding
Trade restrictions
Cannabidiol and Marihuana Research Expansion Act
Introduced: June 27, 2019
See on congress.gov
Everywhere this bill has been
10 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 16, 2020
Held at the desk.
Dec 16, 2020
Received in the House.
Dec 16, 2020
Message on Senate action sent to the House.
Dec 15, 2020
Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR S7504-7507)
Dec 15, 2020
Passed/agreed to in Senate: Passed Senate with an amendment by Voice Vote.(text of amendment in the nature of a substitute: CR S7504-7507)
Dec 15, 2020
Measure laid before Senate by unanimous consent. (consideration: CR S7508)
Dec 15, 2020
Senate Committee on the Judiciary discharged by Unanimous Consent.
Oct 23, 2019
Committee on United States Senate Caucus on International Narcotics Control. Hearings held. Hearings printed: S.Hrg. 116-252.
Jun 27, 2019
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S4633-4634)
Jun 27, 2019
Introduced in Senate
Plain-English summary
Cannabidiol and Marihuana Research Expansion Act
This bill modifies provisions concerning the federal regulation of certain drugs that are deemed to pose a risk of abuse and dependence to facilitate research on, and the use of, medical treatments containing marijuana and its derivatives.
What's happening now
Held at the desk.
Committees of jurisdiction
2